U.S. Markets close in 20 mins.

Momenta Pharmaceuticals, Inc. (MNTA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
16.73+0.18 (+1.06%)
As of 3:39PM EDT. Market open.
People also watch
Full screen
Previous Close16.55
Bid16.70 x 1200
Ask16.75 x 700
Day's Range16.46 - 16.90
52 Week Range10.50 - 19.90
Avg. Volume813,158
Market Cap1.24B
PE Ratio (TTM)-40.11
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters5 days ago

    U.S. jury sides with Amphastar over Momenta in drug patent trial

    A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox. The verdict by the jury in Boston came in a lawsuit by Cambridge, Massachusetts-based biotechnology company Momenta and its partner, Novartis AG's Sandoz unit, that sought nearly $940 million in damages. The jury found that while Rancho Cucamonga, California-based Amphastar had infringed Momenta's patent, it was invalid and unenforceable.

  • American City Business Journals5 days ago

    ​Jury nixes Momenta patent case that sought $938M in damages

    A federal jury has rejected a $938 million lawsuit filed by Momenta Pharmaceuticals that accused a California drugmaker of infringing its patent covering a generic blood-thinner. According to court records, the jury ruled Friday that while Amphastar Pharmaceuticals (AMPH) infringed Momenta’s (MNTA) patent for testing the quality of batches of the drug, the patent was invalid. Momenta and its partner, Novartis unit Sandoz, had sought $938 million in damages in the trial, which began July 11.

  • Capital Cube16 days ago

    ETFs with exposure to Momenta Pharmaceuticals, Inc. : July 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Momenta Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to MNTA-US. Comparing the performance and risk of Momenta Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)